Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Blue Jet Healthcare Limited (BLUEJET.NS)
Thane, IN
Blue Jet Healthcare Ltd. is a company that focuses on the manufacturing and supply of pharmaceutical intermediates and active pharmaceutical ingredients (APIs), which are critical components for the pharmaceutical and healthcare sectors. Its product offerings include integrated intermediates used in contrast media, saccharin and its associated salts, and a range of specialized pharmaceutical intermediates and APIs. The company also delivers comprehensive contract development and manufacturing (CDMO/CMO) and development services. Founded in 1968, Blue Jet Healthcare is headquartered in Thane, India, and maintains a broad international operational footprint across countries such as India, Norway, the United States, Sweden, Italy, and Spain.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +9.15% | +10.93% | +19.35% | +20.43% | -14.71% | -9.20% | -40.62% | +16.45% | +16.45% | +16.45% | +16.45% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 2 | 0 |
-
Revenue growth Biotechnology: +1.6%-8.0% Q1'26: -31.1% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-18.8% Q1'26: -41.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+30.4% Q1'26: +34.8% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+28.5% ★ Q1'26: +27.6% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+19.6% ★ Q1'26: +18.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.1% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.14× ★ Q1'26: 0.15× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 5 Rev. Ana. 5 EPS Ana. |
Mar 2027 6 Rev. Ana. 5 EPS Ana. |
Mar 2028 6 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
7.10B
est: 6.95B (+2.2%)
|
10.30B
est: 10.05B (+2.5%)
|
9.89B
9.08B – 12.34B
-1.6% YoY
|
11.97B
9.12B – 15.96B
+21.1% YoY
|
13.88B
13.13B – 14.62B
+15.9% YoY
|
| EBITDA |
2.48B
est: 2.69B (-7.5%)
|
4.24B
est: 3.89B (+9.1%)
|
3.82B
3.51B – 4.77B
-1.6% YoY
|
4.63B
3.52B – 6.17B
+21.1% YoY
|
5.36B
5.07B – 5.65B
+15.9% YoY
|
| EBIT |
2.20B
est: 2.46B (-10.4%)
|
4.06B
est: 3.56B (+14.3%)
|
3.50B
3.21B – 4.36B
-1.6% YoY
|
4.23B
3.23B – 5.65B
+21.1% YoY
|
4.91B
4.64B – 5.17B
+15.9% YoY
|
| Net Income |
1.64B
est: 1.57B (+4.0%)
|
3.05B
est: 3.59B (-14.9%)
|
2.42B
2.30B – 3.42B
-32.5% YoY
|
2.86B
2.54B – 4.85B
+18.0% YoY
|
3.20B
3.10B – 4.11B
+12.1% YoY
|
| SGA |
272.50M
est: 450.30M (-39.5%)
|
609.97M
est: 651.36M (-6.4%)
|
640.71M
588.19M – 799.67M
-1.6% YoY
|
775.82M
590.94M – 1.03B
+21.1% YoY
|
899.11M
850.75M – 947.47M
+15.9% YoY
|
| EPS |
9.44
est: 9.08 (+4.0%)
|
17.59
est: 16.85 (+4.4%)
|
14.81
13.25 – 19.68
-12.1% YoY
|
18.33
14.65 – 27.95
+23.7% YoY
|
21.32
17.90 – 23.68
+16.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-25 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 100.5K | 0.65% |
| 2 | WisdomTree India Earnings Fund EPI | 0.01% | 228.0K | 0.84% |
| 3 | State Street SPDR Portfolio Emerging Markets ETF SPEM | 0.01% | 913.1K | 0.07% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Shiven Akshay Arora | MD & Director | 52M | male |
| Naresh Suryakant Shah | Executive Director | 40M | male |
| Akshay Bansarilal Arora | Executive Chairman | 36M | male |
| Popat Kedar | Whole-Time Director | 2M | male |
| Payal Gandhi | Chief Business Strategy Officer | — | female |
| Sweta Poddar | Company Secretary & Compliance Officer | — | female |
| Vimalendu Kumar Singh | Chief Operating Officer | — | male |
| Archana Akshay Arora | Head of Business Development | — | female |
| Chandrashekar Parenky | President of Research & Development | — | male |
| Ganesh Karuppannan | Chief Financial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BLUEJET.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
